Roquefort Therapeutics plc (LON:COIL – Get Free Report)’s share price dropped 2.6% on Thursday . The company traded as low as GBX 9 and last traded at GBX 9.26. Approximately 180,732 shares traded hands during mid-day trading, a decline of 21% from the average daily volume of 229,381 shares. The stock had previously closed at GBX 9.50.
Roquefort Therapeutics Stock Performance
The company has a market capitalization of £38.41 million, a price-to-earnings ratio of -0.42 and a beta of 0.05. The company has a current ratio of 0.63, a quick ratio of 3.07 and a debt-to-equity ratio of 8.18. The company has a fifty day moving average of GBX 9.89 and a 200-day moving average of GBX 9.97.
About Roquefort Therapeutics
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.
Further Reading
- Five stocks we like better than Roquefort Therapeutics
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
